CL2018000430A1 - Compuesto de hidroxitriazina y uso médico relacionado. - Google Patents
Compuesto de hidroxitriazina y uso médico relacionado.Info
- Publication number
- CL2018000430A1 CL2018000430A1 CL2018000430A CL2018000430A CL2018000430A1 CL 2018000430 A1 CL2018000430 A1 CL 2018000430A1 CL 2018000430 A CL2018000430 A CL 2018000430A CL 2018000430 A CL2018000430 A CL 2018000430A CL 2018000430 A1 CL2018000430 A1 CL 2018000430A1
- Authority
- CL
- Chile
- Prior art keywords
- medical use
- related medical
- compound
- hydroxytriazine
- hydroxytriazine compound
- Prior art date
Links
- -1 Hydroxytriazine compound Chemical class 0.000 title 1
- 102100033076 Prostaglandin E synthase Human genes 0.000 abstract 2
- 101710096361 Prostaglandin E synthase Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015160284 | 2015-08-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018000430A1 true CL2018000430A1 (es) | 2018-08-03 |
Family
ID=58052084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018000430A CL2018000430A1 (es) | 2015-08-17 | 2018-02-16 | Compuesto de hidroxitriazina y uso médico relacionado. |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20170057943A1 (enExample) |
| EP (2) | EP4046991A1 (enExample) |
| JP (4) | JP2017039714A (enExample) |
| KR (1) | KR20180037270A (enExample) |
| CN (1) | CN108137515B (enExample) |
| AR (1) | AR105711A1 (enExample) |
| AU (1) | AU2016309337B2 (enExample) |
| BR (1) | BR112018001809A2 (enExample) |
| CA (1) | CA2992410A1 (enExample) |
| CL (1) | CL2018000430A1 (enExample) |
| CO (1) | CO2018002516A2 (enExample) |
| IL (1) | IL257559B (enExample) |
| MX (1) | MX375283B (enExample) |
| PE (1) | PE20180951A1 (enExample) |
| PH (1) | PH12018500181A1 (enExample) |
| SG (1) | SG11201800698VA (enExample) |
| TW (1) | TWI704139B (enExample) |
| WO (1) | WO2017030115A1 (enExample) |
| ZA (1) | ZA201801134B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI651310B (zh) | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
| JP2017039714A (ja) * | 2015-08-17 | 2017-02-23 | 日本たばこ産業株式会社 | ヒドロキシトリアジン化合物及びその医薬用途 |
| US10710967B2 (en) * | 2015-10-29 | 2020-07-14 | Aska Pharmaceutical Co., Ltd. | Pyrimidine derivative |
| RU2648181C1 (ru) * | 2017-05-25 | 2018-03-22 | Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ лечения нейроретинопатии вследствие тяжелой преэклампсии |
| CN110799506B (zh) * | 2017-06-26 | 2024-03-01 | 默克专利有限公司 | 用于制备被取代的含氮杂环化合物的方法 |
| KR20250030486A (ko) * | 2022-07-06 | 2025-03-05 | 아스카 세이야쿠 가부시키가이샤 | 피리미딘 유도체 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH473818A (de) | 1964-03-18 | 1969-06-15 | Ciba Geigy | Verfahren zur Herstellung von neuen Hydroxyphenyl-1,3,5-triazinen und deren Verwendung |
| SU1313854A1 (ru) | 1985-04-17 | 1987-05-30 | Институт Органической Химии Ан Армсср | Способ получени смеси 2-оксо-2,3-дигидро-4,6,-бис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина и 2,4,6-трис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина |
| DE19543730A1 (de) | 1995-11-23 | 1997-05-28 | Ciba Geigy Ag | Bis-Resorcinyl-Triazine |
| US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
| US6410729B1 (en) | 1996-12-05 | 2002-06-25 | Amgen Inc. | Substituted pyrimidine compounds and methods of use |
| ZA9710727B (en) | 1996-12-05 | 1998-06-12 | Amgen Inc | Substituted pyrimidine compounds and methods of use. |
| WO1998024782A2 (en) | 1996-12-05 | 1998-06-11 | Amgen Inc. | Substituted pyrimidine compounds and their use |
| GB9726987D0 (en) | 1997-12-22 | 1998-02-18 | Glaxo Group Ltd | Compounds |
| EA004656B1 (ru) | 1999-04-01 | 2004-06-24 | Пфайзер Продактс Инк. | Аминопиримидины в качестве ингибиторов сорбитолдегидрогеназы |
| ES2398854T3 (es) | 2007-04-03 | 2013-03-22 | E. I. Du Pont De Nemours And Company | Fungicidas de benceno sustituido |
| JP5388270B2 (ja) | 2008-06-04 | 2014-01-15 | 株式会社Ａｄｅｋａ | ２，４，６−トリス（ヒドロキシフェニル）−１，３，５−トリアジン化合物の製造方法 |
| US8716474B2 (en) | 2008-06-04 | 2014-05-06 | Adeka Corporation | Method for producing 2,4,6-tris(hydroxyphenyl)-1,3,5-triazine compound |
| EP2138488A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases |
| GB2463788B (en) * | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| CN101747282A (zh) | 2008-12-10 | 2010-06-23 | 上海特化医药科技有限公司 | 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途 |
| AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
| WO2011037610A1 (en) * | 2009-09-23 | 2011-03-31 | Albert Einstein College Of Medicine Of Yeshiva University | Prostaglandin transporter inhibitors and uses thereof |
| WO2011048004A1 (en) | 2009-10-23 | 2011-04-28 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin e2 synthase-1 |
| US8586604B2 (en) | 2010-08-20 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
| AR086254A1 (es) | 2011-05-26 | 2013-11-27 | Lilly Co Eli | Derivados de imidazol utiles para el tratamiento de artritis |
| FR2983859B1 (fr) | 2011-12-12 | 2014-01-17 | Sanofi Sa | Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique |
| CA2873984A1 (en) | 2012-05-23 | 2013-11-28 | Stemergie Biotechnology Sa | Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof |
| TWI568722B (zh) * | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| WO2015059618A1 (en) * | 2013-10-22 | 2015-04-30 | Glenmark Pharmaceuticals S.A. | SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS |
| TWI651310B (zh) | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
| CN105586773A (zh) | 2014-11-13 | 2016-05-18 | 东丽纤维研究所（中国）有限公司 | 一种拒水抗紫外纺织品及其生产方法和用途 |
| JP2017039714A (ja) * | 2015-08-17 | 2017-02-23 | 日本たばこ産業株式会社 | ヒドロキシトリアジン化合物及びその医薬用途 |
-
2016
- 2016-08-16 JP JP2016159454A patent/JP2017039714A/ja not_active Ceased
- 2016-08-16 CN CN201680060597.6A patent/CN108137515B/zh active Active
- 2016-08-16 PE PE2018000185A patent/PE20180951A1/es unknown
- 2016-08-16 US US15/237,763 patent/US20170057943A1/en not_active Abandoned
- 2016-08-16 EP EP22162814.2A patent/EP4046991A1/en active Pending
- 2016-08-16 MX MX2018002044A patent/MX375283B/es active IP Right Grant
- 2016-08-16 TW TW105126071A patent/TWI704139B/zh not_active IP Right Cessation
- 2016-08-16 AU AU2016309337A patent/AU2016309337B2/en not_active Ceased
- 2016-08-16 CA CA2992410A patent/CA2992410A1/en active Pending
- 2016-08-16 KR KR1020187007349A patent/KR20180037270A/ko not_active Ceased
- 2016-08-16 AR ARP160102503A patent/AR105711A1/es unknown
- 2016-08-16 EP EP16837104.5A patent/EP3339296A4/en not_active Withdrawn
- 2016-08-16 BR BR112018001809-0A patent/BR112018001809A2/pt not_active Application Discontinuation
- 2016-08-16 WO PCT/JP2016/073879 patent/WO2017030115A1/ja not_active Ceased
- 2016-08-16 SG SG11201800698VA patent/SG11201800698VA/en unknown
-
2018
- 2018-01-24 PH PH12018500181A patent/PH12018500181A1/en unknown
- 2018-02-15 IL IL257559A patent/IL257559B/en unknown
- 2018-02-16 CL CL2018000430A patent/CL2018000430A1/es unknown
- 2018-02-19 ZA ZA2018/01134A patent/ZA201801134B/en unknown
- 2018-03-12 CO CONC2018/0002516A patent/CO2018002516A2/es unknown
-
2020
- 2020-03-03 US US16/807,719 patent/US20210024486A1/en not_active Abandoned
- 2020-09-04 JP JP2020148973A patent/JP2020193235A/ja not_active Ceased
-
2022
- 2022-08-12 JP JP2022128590A patent/JP2022163169A/ja active Pending
-
2023
- 2023-02-24 US US18/114,043 patent/US12492182B2/en active Active
- 2023-12-08 JP JP2023207429A patent/JP7640658B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010140A (es) | Nuevos metodos. | |
| PH12020500066A1 (en) | Carboxamides as modulators of sodium channels | |
| CL2018000430A1 (es) | Compuesto de hidroxitriazina y uso médico relacionado. | |
| MX391850B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX387322B (es) | Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1). | |
| JOP20180025A1 (ar) | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك | |
| CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
| BR112018005905A2 (pt) | ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto? | |
| NZ721500A (en) | Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury | |
| EA201890449A1 (ru) | Фумагиллиновые гетероциклические соединения и способы их получения и применения | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| SG11202007082PA (en) | Composition used for therapeutic treatment of skin disease | |
| MX2021000542A (es) | Apirasas solubilizadas, metodos y usos. | |
| UA118474C2 (uk) | (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині | |
| PE20181450A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| EP3639842A4 (en) | Pharmaceutical composition containing gly-thymosin 4 (gly-t 4) for treatment of dry eye | |
| CL2017002229A1 (es) | Inhibidores de bace1. | |
| EA201792558A1 (ru) | Противогрибковый 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-триазол-1-ил)метил)-5-(2,4-дифторфенил)тетрагидрофуран-3-ил)метокси)-3-метилфенил)пиперазин-1-ил)-n-(2-гидроксициклогексил)бензамид или его фармацевтически приемлемая соль | |
| MX384394B (es) | Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas. | |
| MX385725B (es) | Composición farmacéutica que comprende sumatriptán para tratamiento de migraña. | |
| MX375329B (es) | 2,2,2-trifluoroetil-tiadiazinas. | |
| EA202090268A1 (ru) | Карбоксамиды в качестве модуляторов натриевых каналов |